Cost factors drive collaboration with clinics and doctor groups.
mPulse Mobile has closed an $11 million Series B funding round, bringing its total amount of raised capital to more than $25 million.
Second Sight Medical Products Inc. in Sylmar announced Monday that it had entered into a $10 million stock purchase agreement with entities owned by the company’s Chairman Gregg Williams
Henry Mayo Newhall Hospital in Valencia has launched its own clinically integrated network, or CIN, a collection of physicians and clinics that coordinate patient care with the objective of improving customer satisfaction and lowering costs.
The stock of MannKind Corp. jumped on Wednesday following news that the Food and Drug Administration would no longer require the company to adhere to a special plan to communicate the risks and benefits of its inhalable insulin Afrezza.
Amgen Inc. beat Wall Street expectations for earnings and revenue in its first fiscal quarter.
Amgen Inc. said a new study showed its drug Aimovig is an effective preventive treatment migraine patients who have tried other treatments that either didn’t work or had intolerable side effects, the company announced Tuesday.
Skin treatments provide youthful edge for older job-seekers and executives.
Shares of Simulations Plus Inc. rose more than 6 percent Tuesday after the company reported results for its second fiscal quarter.
Amgen Inc. will build a new manufacturing plant at the site of its existing facilities in West Greenwich, R.I., the pharma company announced Tuesday.
Shares of MannKind Corp. fell nearly 25 percent Friday, after the company announced a $28 million stock offering.
Amgen Inc.’s bone drug Xgeva has been approved by the European Commission for the prevention of skeletal complications in patients with multiple myeloma, a bone marrow cancer.
Apollo Medical Holdings Inc. has announced its fiscal year results, but the financial numbers only reflect 23 days’ of the company’s performance.
Amgen Inc.’s leukemia drug Blincyto has become the first drug to be approved by the Food and Drug Administration for use in a subgroup of leukemia patients who are at a high risk of relapse following initial treatment.
Sienna Biopharmaceuticals Inc., an aesthetic dermatological product company based in Westlake Village, has hired Allergan Inc. senior marketing manager Caroline Van Hove as its chief commercial officer.